Pirtobrutinib (JAYPIRCA)

Bruton tyrosine kinase (BTK) inhibitor (non-covalent, targeted anticancer therapy)

Pirtobrutinib (JAYPIRCA)

Forms and strengths
Form: TabletStrength: 50 mg, 100 mg
Print

Indication

  • Pirtobrutinib is used as a single agent to treat adults with mantle cell lymphoma that has relapsed or is refractory after at least two prior lines of therapy, including a BTK inhibitor.
  • Pirtobrutinib is used as a single agent to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
  • Pirtobrutinib was authorized in Canada under a Notice of Compliance with Conditions, based on promising early evidence, pending results of trials to confirm its clinical benefit.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.